|
Video: What is a Stock Split?
|
|
Cara Therapeutics is an early commercial-stage biopharmaceutical company focusing on a new treatment paradigm to improve the lives of patients suffering from pruritus. Co.'s KORSUVA injection is an FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease, in adults undergoing hemodialysis. Co. is developing an Oral KORSUVA (difelikefalin) formulation for the treatment of pruritus in patients with atopic dermatitis, and non-dialysis-dependent chronic kidney disease. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis, and in notalgia paresthetica patients with moderate-to-severe pruritus. According to our Cara Therapeutics stock split history records, Cara Therapeutics has had 0 splits. | |
|
Cara Therapeutics (CARA) has 0 splits in our Cara Therapeutics stock split history database.
Looking at the Cara Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cara Therapeutics shares, starting with a $10,000 purchase of CARA, presented on a split-history-adjusted basis factoring in the complete Cara Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/28/2014 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$13.37 |
|
End price/share: |
$0.70 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-94.76% |
|
Average Annual Total Return: |
-25.54% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$523.88 |
|
Years: |
10.00 |
|
|
|
|
|